Co-receptor tropism has been identified to correlate with HIV-1 transmission and the disease progression in patients. A molecular epidemiology investigation of co-receptor tropism is important for ...

The US Food and Drug Administration has approved afamitresgene autoleucel (afami-cel) (Tecelra, Adaptimmune LLC) to treat advanced synovial sarcoma. Afami-cel — the first engineered cell therapy for a ...

Imagine your immune cells could be modified to attack any kind of cancer. T cell receptor (TCR) therapy has the potential to one day become a universal cancer treatment. But there are risks.

Chinese Medical Journals Publishing House Co., Ltd. Brain cancer is one of the most aggressive and life-threatening diseases, with glioblastoma (GBM) being the most common and deadliest type. Patients ...

The FDA approved afamitresgene autoleucel, or afami-cel (Tecelra), as the first T-cell receptor therapy for cancer. Afami-cel is made by collecting a patient’s T-cells, genetically modifying them and ...

The FDA approved denileukin diftitox (Lymphir), the first novel targeted systemic therapy approved for relapsed/refractory (r/r) cutaneous T-cell lymphoma (CTCL) since 2018, Citius Pharmaceuticals ...

TScan Therapeutics is laying off 30% of its workforce as the T-cell receptor (TCR) therapy biotech abandons a phase 1 solid tumor trial and focuses on patients with blood cancers. The company had ...

AstraZeneca has dropped the lead candidate from its $200 million buyout of Neogene Therapeutics as part of a wider cell therapy clearout. When AstraZeneca scooped up the company back in 2022, ...